Standard BioTools Inc. (LAB)Healthcare | Medical Devices | Boston, United States | NasdaqGS
0.85 USD
+0.01
(1.516%)
⇧
(July 15, 2026, 12:20 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:07 a.m. EDT
The investment case for Standard BioTools is currently broken by a severe lack of profitability and a deteriorating multi-year price trajectory. Despite a fortress-like balance sheet with minimal debt and massive cash reserves relative to operations, the company is burning cash with negative operating and free cash flows while posting negative returns on both assets and equity. The market has punished this reality hard, driving the stock down 87% over the last nine years. While the recent merger announcement with Treeline Biosciences offers a potential strategic pivot, the current fundamentals do not support a recovery thesis yet. The heavy options activity focused on downside protection confirms that the market remains deeply skeptical of a near-term bounce, viewing the current price as a continuation of a long-term decline rather than a bottom. Until the merger closes and demonstrates a clear path to restoring profitability, the risk-reward profile remains skewed heavily toward the downside. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.118151 |
| AutoTheta | 0.131867 |
| AutoETS | 0.136437 |
| MSTL | 0.137871 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 1.79 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.450 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.256 |
| Revenue per Share | 0.225 |
| Market Cap | 332,978,368 |
| Forward P/E | -85.06 |
| Beta | 1.42 |
| Profit Margins | 90.67% |
| Previous Name | Fluidigm Corporation |
| Website | https://www.standardbio.com |
As of July 11, 2026, 6:07 a.m. EDT: Options activity reveals a distinct defensive posture rather than speculative aggression. Put open interest significantly outweighs call open interest across all expirations, particularly in the November 2026 window where put volume and open interest are nearly triple those of calls. This heavy concentration of downside protection suggests investors are hedging against further declines or anticipating a continued struggle to recover from recent lows, rather than betting on an immediate rebound.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.32258064 |
| Address1 | 50 Milk Street |
| Address2 | 10th Floor |
| All Time High | 49.46 |
| All Time Low | 0.7 |
| Ask | 1.08 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 3,509,730 |
| Average Daily Volume3 Month | 3,680,711 |
| Average Volume | 3,680,711 |
| Average Volume10Days | 3,509,730 |
| Beta | 1.422 |
| Bid | 0.5942 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 1.438 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.8506 |
| Current Ratio | 12.356 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.8673 |
| Day Low | 0.8267 |
| Debt To Equity | 5.256 |
| Display Name | Standard BioTools |
| Earnings Call Timestamp End | 1,778,011,200 |
| Earnings Call Timestamp Start | 1,778,011,200 |
| Earnings Timestamp | 1,778,011,200 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | -68,210,000 |
| Ebitda Margins | -0.79079 |
| Enterprise To Ebitda | 1.445 |
| Enterprise To Revenue | -1.143 |
| Enterprise Value | -98,595,552 |
| Eps Current Year | 0.03 |
| Eps Forward | -0.01 |
| Eps Trailing Twelve Months | -0.13 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 871 7152 |
| Fifty Day Average | 0.9462 |
| Fifty Day Average Change | -0.09560001 |
| Fifty Day Average Change Percent | -0.10103573 |
| Fifty Two Week Change Percent | -32.258064 |
| Fifty Two Week High | 1.72 |
| Fifty Two Week High Change | -0.8694 |
| Fifty Two Week High Change Percent | -0.50546515 |
| Fifty Two Week Low | 0.7 |
| Fifty Two Week Low Change | 0.15060002 |
| Fifty Two Week Low Change Percent | 0.21514289 |
| Fifty Two Week Range | 0.7 - 1.72 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,297,348,200,000 |
| Float Shares | 209,455,918 |
| Forward Eps | -0.01 |
| Forward P E | -85.060005 |
| Free Cashflow | -13,438,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 385 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.5327 |
| Gross Profits | 45,948,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.016900001 |
| Held Percent Institutions | 0.76781 |
| Implied Shares Outstanding | 391,462,923 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts. |
| Long Name | Standard BioTools Inc. |
| Market | us_market |
| Market Cap | 332,978,368 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_742365 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-15 |
| Net Income To Common | -50,082,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 326,988,979 |
| Number Of Analyst Opinions | 2 |
| Open | 0.8267 |
| Operating Cashflow | -90,657,000 |
| Operating Margins | -0.44529 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 266 6000 |
| Prev Name | Fluidigm Corporation |
| Previous Close | 0.8379 |
| Price Eps Current Year | 28.353334 |
| Price Hint | 4 |
| Price To Book | 0.591516 |
| Price To Sales Trailing12 Months | 3.860395 |
| Profit Margins | 0.90667 |
| Quick Ratio | 11.772 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.012700021 |
| Regular Market Change Percent | 1.5156965 |
| Regular Market Day High | 0.8673 |
| Regular Market Day Low | 0.8267 |
| Regular Market Day Range | 0.8267 - 0.8673 |
| Regular Market Open | 0.8267 |
| Regular Market Previous Close | 0.8379 |
| Regular Market Price | 0.8506 |
| Regular Market Time | 1,784,132,409 |
| Regular Market Volume | 761,602 |
| Return On Assets | -0.080520004 |
| Return On Equity | -0.09861 |
| Revenue Growth | 0.046 |
| Revenue Per Share | 0.225 |
| Sand P52 Week Change | 0.2043345 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 391,462,923 |
| Shares Percent Shares Out | 0.0087 |
| Shares Short | 3,425,003 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 13,127,631 |
| Short Name | Standard BioTools Inc. |
| Short Percent Of Float | 0.0145000005 |
| Short Ratio | 0.58 |
| Source Interval | 15 |
| State | MA |
| Symbol | LAB |
| Target High Price | 1.75 |
| Target Low Price | 1.35 |
| Target Mean Price | 1.55 |
| Target Median Price | 1.55 |
| Total Cash | 455,176,000 |
| Total Cash Per Share | 1.166 |
| Total Debt | 29,491,000 |
| Total Revenue | 86,255,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.15785 |
| Two Hundred Day Average Change | -0.30725002 |
| Two Hundred Day Average Change Percent | -0.26536253 |
| Type Disp | Equity |
| Volume | 761,602 |
| Website | https://www.standardbio.com |
| Zip | 2,109 |